1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Stem Cell/Wnt
  3. JAK
  4. JAK3 Inhibitors

JAK3 Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform JAK3 together.

Please try each isoform separately.

JAK3 Specific Inhibitors
Product Name JAK3 JAK1 JAK2 Tyk2 JAK3 Selectivity Purity
Tofacitinib
JAK3, IC50: 1 nM
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
  Selective Inhibitor 99.96%
Tofacitinib citrate
JAK3, IC50: 1 nM
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
  Selective Inhibitor 99.92%
PF-06651600
JAK3, IC50: 33.1 nM
      Selective Inhibitor 99.98%
FM381
JAK3, IC50: 127 pM
      Selective Inhibitor 98.41%
JANEX-1
JAK3, IC50: 78 μM
      Selective Inhibitor 99.84%
ZM39923 hydrochloride
JAK3, pIC50: 7.1
JAK1, pIC50: 4.4
    Selective Inhibitor >98.0%
WHI-P154
JAK3, IC50: 1.8 μM
      Selective Inhibitor 98.60%
JAK3-IN-1
JAK3, IC50: 4.8 nM
JAK1, IC50: 896 nM
JAK2, IC50: 1050 nM
  Selective Inhibitor 99.98%
WHI-P97
JAK3, IC50: 11 μM
      Selective Inhibitor 99.48%
JAK3 covalent inhibitor-1
JAK3, IC50: 11 nM
      Selective Inhibitor
ZM39923
JAK3, pIC50: 7.1
JAK1, pIC50: 4.4
    Selective Inhibitor
JAK3-IN-7
JAK3, IC50: 0.01 μM
      Selective Inhibitor
Ruxolitinib
JAK3, IC50: 428 nM
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
Tyk2, IC50: 19 nM
Pan Inhibitor 99.99%
Ruxolitinib phosphate
JAK3, IC50: 428 nM
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
Tyk2, IC50: 19 nM
Pan Inhibitor 99.89%
Baricitinib
JAK3, IC50: 560 nM
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
Tyk2, IC50: 53 nM
Pan Inhibitor 99.93%
Pacritinib
JAK3, IC50: 520 nM
JAK1, IC50: 1280 nM
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
Tyk2, IC50: 50 nM
Pan Inhibitor 99.66%
Momelotinib
JAK3, IC50: 155 nM
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
  Pan Inhibitor 98.11%
Filgotinib
JAK3, IC50: 810 nM
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
Tyk2, IC50: 116 nM
Pan Inhibitor 99.64%
AT9283
JAK3, IC50: 1.1 nM
 
JAK2, IC50: 1.2 nM
  Pan Inhibitor 99.61%
Peficitinib
JAK3, IC50: 0.7 nM
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
Tyk2, IC50: 4.8 nM
Pan Inhibitor 99.43%
Cerdulatinib
JAK3, IC50: 8 nM
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
Tyk2, IC50: 0.5 nM
Pan Inhibitor 99.00%
Gandotinib
JAK3, IC50: 48 nM
 
JAK2, IC50: 3 nM
Tyk2, IC50: 44 nM
Pan Inhibitor 99.96%
Pyridone 6
JAK3, IC50: 5 nM
Murine JAK1, IC50: 15 nM
JAK2, IC50: 1 nM
Tyk2, IC50: 1 nM
Pan Inhibitor 98.04%
Delgocitinib
JAK3, IC50: 13 nM
JAK1, IC50: 2.8 nM
JAK2, IC50: 2.6 nM
Tyk2, IC50: 58 nM
Pan Inhibitor 99.14%
TG101209
JAK3, IC50: 169 nM
 
JAK2, IC50: 6 nM
  Pan Inhibitor 98.94%
Oclacitinib maleate
JAK3, IC50: 99 nM
JAK1, IC50: 10 nM
JAK2, IC50: 18 nM
Tyk2, IC50: 84 nM
Pan Inhibitor 99.53%
CEP-33779
JAK3, IC50: 150 nM
 
JAK2, IC50: 1.8 nM
  Pan Inhibitor 98.04%
BMS-911543
JAK3, IC50: 360 nM
JAK1, IC50: 75 nM
JAK2, IC50: 1.1 nM
Tyk2, IC50: 66 nM
Pan Inhibitor 98.12%
SAR-20347
JAK3, IC50: 41 nM
JAK1, IC50: 23 nM
JAK2, IC50: 26 nM
Tyk2, IC50: 0.6 nM
Pan Inhibitor 97.00%
Ilginatinib
JAK3, IC50: 39 nM
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
Tyk2, IC50: 22 nM
Pan Inhibitor 95.88%
PF-06700841 P-Tosylate
JAK3, IC50: 6.9 μM
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
  Pan Inhibitor 99.66%
Baricitinib phosphate
JAK3, IC50: 560 nM
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
Tyk2, IC50: 53 nM
Pan Inhibitor 99.49%
AZ960
JAK3, IC50: 9 nM
 
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
  Pan Inhibitor >98.0%
NVP-BSK805 dihydrochloride
JAK3 JH1, IC50: 18.68 nM
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
TYK2 JH1, IC50: 10.76 nM
Pan Inhibitor 99.36%
Decernotinib
JAK3, Ki: 2.5 nM
JAK1, Ki: 11 nM
JAK2, Ki: 13 nM
Tyk2, Ki: 11 nM
Pan Inhibitor 98.91%
XL019
JAK3, IC50: 214.2 nM
 
JAK2, IC50: 2.2 nM
  Pan Inhibitor >98.0%
Ilginatinib maleate
JAK3, IC50: 39 nM
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
Tyk2, IC50: 22 nM
Pan Inhibitor 97.04%
JAK/HDAC-IN-1
JAK3, IC50: 7.4 nM
JAK1, IC50: 4.8 nM
JAK2, IC50: 4 nM
Tyk2, IC50: 49 nM
Pan Inhibitor 98.04%
Ilginatinib hydrochloride
JAK3, IC50: 39 nM
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
Tyk2, IC50: 22 nM
Pan Inhibitor 98.02%
PF-06700841
JAK3, IC50: 6.9 μM
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
  Pan Inhibitor
GLPG0634 analog
JAK3, IC50: <100 nM
   
Tyk2, IC50: <100 nM
Pan Inhibitor 98.00%
Momelotinib sulfate
JAK3, IC50: 155 nM
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
  Pan Inhibitor >96.0%
NVP-BSK805
JAK3 JH1, IC50: 18.68 nM
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
TYK2 JH1, IC50: 10.76 nM
Pan Inhibitor
JAK2/FLT3-IN-1
JAK3, IC50: 39 nM
JAK1, IC50: 26 nM
JAK2, IC50: 0.7 nM
  Pan Inhibitor
PF-06263276
JAK3, IC50: 59.9 nM
JAK1, IC50: 2.2 nM
JAK2, IC50: 23.1 nM
Tyk2, IC50: 29.7 nM
Pan Inhibitor
JAK-IN-3
JAK3, IC50: 3 nM
JAK1, IC50: 5 nM
JAK2, IC50: 70 nM
Tyk2, IC50: 34 nM
Pan Inhibitor
JAK3-IN-6
JAK3, IC50: 0.15 nM
      Pan Inhibitor 98.07%
Momelotinib Mesylate
JAK3, IC50: 155 nM
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
  Pan Inhibitor
Ruxolitinib sulfate
JAK3, IC50: 428 nM
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
Tyk2, IC50: 19 nM
Pan Inhibitor